Aouam A, Marmouch H, Kooli I, Marrakchi W, Hellara I, Neffati F, Najjar F, Chakroun M
Service des Maladies Infectieuses, EPS Fattouma Bourguiba, 5019 Monastir, Tunisie.
Service d'endocrinologie et de médecine interne, EPS Fattouma Bourguiba, 5019 Monastir, Tunisie.
Ann Pharm Fr. 2021 Jul;79(4):465-472. doi: 10.1016/j.pharma.2021.01.005. Epub 2021 Jan 28.
Metabolic abnormalities are frequently reported in HIV infection. They were mainly related to the chronic infection and the use of antiretroviral therapy.
Describe the epidemiological, clinical, laboratory and treatment features of people living with HIV (PLHIV) on antiretroviral therapy and determine the prevalence of metabolic syndrome and its associated factors.
We conducted a cross-sectional, descriptive and analytical study in the service of Infectious Diseases of the University Hospital of Monastir. We included all PLHIV on antiretroviral therapy for at least 3 months. Biological explorations based on metabolic parameters were performed systematically for all patients after informed consent. Metabolic syndrome was assessed according to the definitions of the International Diabetes Federation (IDF) in 2005. We divided the patients into two groups: Group A: PLHIV with metabolic syndrome (n=19) and Group B: PLHIV without metabolic syndrome (n=51).
We included in this study 70 PLVIH. The metabolic syndrome was noted in 19 cases (27.1%). The average age was 43.7 years in group A and 36.7 years in group B. Gender distribution were uniform in the two groups (P=0.4). HIV infection has been evolving for 9.7 and 5.8 years respectively in group A and B, P=0.017. Body mass index (BMI) was significantly higher in group A (26.4 vs 23.5kg/m, P=0.008). Two patients in group A (10.5%) and 14 patients in group B (27.4%) had a low CD4 count (<200/mm). Protease inhibitor regimens were prescribed in five cases (26.3%) in group A and 26 cases (50.9%) in group B. In multivariate models, Age over 40 (OR=9.9, 95% CI 2.4-40.6, P=0.001) and BMI ≥25 Kg/m (OR=8.47, 95% CI 1.94-36.8, p=0.004) were both independently associated with the presence of the metabolic syndrome.
Metabolic syndrome is common among PLHIV on antiretroviral therapy. The identification of factors associated is a main parameter for early detection of metabolic risk and personalized management.
代谢异常在HIV感染中屡有报道。它们主要与慢性感染及抗逆转录病毒治疗的使用有关。
描述接受抗逆转录病毒治疗的HIV感染者(PLHIV)的流行病学、临床、实验室及治疗特征,并确定代谢综合征的患病率及其相关因素。
我们在莫纳斯提尔大学医院传染病科开展了一项横断面、描述性及分析性研究。我们纳入了所有接受抗逆转录病毒治疗至少3个月的PLHIV。在获得知情同意后,对所有患者系统地进行了基于代谢参数的生物学检查。根据2005年国际糖尿病联盟(IDF)的定义评估代谢综合征。我们将患者分为两组:A组:患有代谢综合征的PLHIV(n = 19)和B组:未患有代谢综合征的PLHIV(n = 51)。
本研究纳入了70例PLVIH。19例(27.1%)出现代谢综合征。A组的平均年龄为43.7岁,B组为36.7岁。两组的性别分布均匀(P = 0.4)。A组和B组的HIV感染分别已发展了9.7年和5.8年,P = 0.017。A组的体重指数(BMI)显著更高(26.4 vs 23.5kg/m,P = 0.008)。A组有2例患者(10.5%)和B组有14例患者(27.4%)的CD4细胞计数较低(<200/mm)。A组有5例患者(26.3%)和B组有26例患者(50.9%)采用了蛋白酶抑制剂方案。在多变量模型中,年龄超过40岁(OR = 9.9,95%CI 2.4 - 40.6,P = 0.001)和BMI≥25 Kg/m(OR = 8.47,95%CI 1.94 - 36.8,p = 0.004)均与代谢综合征的存在独立相关。
代谢综合征在接受抗逆转录病毒治疗的PLHIV中很常见。识别相关因素是早期发现代谢风险及个性化管理的主要参数。